Scarica l'app Stockscreener
22.11
3.37%
0.72
Dopo l'orario di chiusura:
22.50
0.39
+1.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$21.39
Aprire:
$21.61
Volume 24 ore:
1.70M
Relative Volume:
0.82
Capitalizzazione di mercato:
$1.50B
Reddito:
$796.00M
Utile/perdita netta:
$-136.49M
Rapporto P/E:
-10.58
EPS:
-2.09
Flusso di cassa netto:
$-64.24M
1 W Prestazione:
+6.61%
1M Prestazione:
+18.81%
6M Prestazione:
+6.50%
1 anno Prestazione:
-32.30%
Intervallo 1D:
$21.32
$22.16
Intervallo di 1 settimana:
$20.27
$22.16
Portata 52W:
$9.98
$38.28
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Confronta TNDM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
22.11 | 1.45B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
128.47 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.19 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.31 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.57 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.38 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Ripresa | Stifel | Hold |
| 2025-09-08 | Iniziato | Oppenheimer | Outperform |
| 2025-08-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Downgrade | Citigroup | Neutral → Sell |
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - TMX Newsfile
Does Tandem Diabetes Care’s Slumping Share Price Signal a New Opportunity in 2025? - Yahoo Finance
Wells Fargo Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM) - The Globe and Mail
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Tandem to pay Roche $36M in patent dispute settlement - MSN
Don't Buy Tandem Diabetes Care Until This Big Thing Happens - AOL.com
(TNDM) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors t - GuruFocus
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action InvestigationTNDM - PR Newswire
Tandem Diabetes Care (TNDM) Sees Target Price Raised by Citigrou - GuruFocus
Tandem Diabetes Care (NASDAQ:TNDM) Has Debt But No Earnings; Should You Worry? - 富途牛牛
Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now - Your Wyoming Link
Did Tandem’s Insulin Pump Correction and Securities Probe Just Shift Tandem Diabetes Care's (TNDM) Investment Narrative? - Sahm
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Tandem Diabetes Care Appoints Sandra Beaver to Board - MSN
How Tandem Diabetes Care Inc. stock valuations compare to rivalsTrade Entry Report & Free Daily Entry Point Trade Alerts - Newser
Is Tandem Diabetes Care Inc. (TD5A) stock resilient in recession scenariosJuly 2025 Trade Ideas & Safe Capital Growth Plans - Newser
Taking Stock of Tandem Diabetes Care (TNDM) Valuation After Fresh Analyst Upgrades and Reaffirmed Optimism - Sahm
DelveInsight expects the Artificial Pancreas Device Market to grow at a CAGR of 16.33% through 2032 - The Globe and Mail
Tandem Diabetes (TNDM) Stock Is Up, What You Need To Know - Finviz
Will Tandem Diabetes Care Inc. (TD5A) stock outperform value peersTrade Analysis Report & Growth Oriented Trade Recommendations - Newser
Tandem Diabetes Care Stock Gains After Analyst Raises Target to $23News and Statistics - IndexBox
Why Tandem Diabetes Care Inc. (TD5A) stock could be top winnerM&A Rumor & Safe Entry Zone Identification - Newser
TNDM SEC FilingsTandem Diabetes 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Tandem Diabetes Care’s (TNDM) Valuation After Legal Probe and t:slim X2 Pump Correction Announcement - Yahoo Finance
TNDM: Morgan Stanley Raises Price Target Amidst Maintained Ratin - GuruFocus
How Tandem Diabetes Care Inc. (TD5A) stock reacts to Fed tightening2025 AllTime Highs & Low Drawdown Investment Strategies - Newser
Free cash flow per share of Tandem Diabetes Care, Inc. – LSE:0M0F - TradingView
(TNDM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How Recent Product Correction and Legal Inquiry May Impact Tandem Diabetes Care’s (TNDM) Investment Outlook - Sahm
Risk Check: What makes Tandem Diabetes Care Inc. (TD5A) stock appealing to growth investorsQuarterly Trade Summary & Weekly High Return Forecasts - moha.gov.vn
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
What risks investors should watch in Tandem Diabetes Care Inc. stockPortfolio Update Report & Verified Short-Term Plans - BỘ NỘI VỤ
A Fresh Look at Tandem Diabetes Care (TNDM) Valuation Following Insulin Pump Device Correction News - Sahm
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
[Form 3] TANDEM DIABETES CARE INC Initial Statement of Beneficial Ownership - Stock Titan
Implantable Insulin Pumps Market Size to Hit USD 14.27 Billion by 2034 - Precedence Research
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), ... - Bakersfield.com
Tandem Diabetes Care Shows Market Leadership With Jump To 83 RS Rating - MSN
Why Tandem Diabetes Care (TNDM) Is Up 14.3% After FDA Clears Android App for Mobi System and What’s Next - Sahm
Align Technology, Tandem Diabetes, Integra LifeSciences, Lantheus, and Inspire Medical Systems Shares Skyrocket, What You Need To Know - Yahoo Finance
Tandem Diabetes Care, Inc.Common Stock (NQ: TNDM - Markets Financial Content
Momentum Stocks November 2025: Tandem Diabetes Sell, Vicor & Cardinal Health BuyNews and Statistics - IndexBox
Why Tandem Diabetes Care Inc. stock is trending among retail tradersTrade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Tandem Diabetes Care Inc. (TD5A) stock a momentum leaderLayoff News & Verified Momentum Stock Alerts - newser.com
Why millennials buy Tandem Diabetes Care Inc. (TD5A) stockJuly 2025 Gainers & Consistent Income Trade Ideas - newser.com
Barclays Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM) - The Globe and Mail
Can Tandem Diabetes Care Inc. stock deliver surprise earnings beatQuarterly Performance Summary & Daily Chart Pattern Signals - newser.com
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.42%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):